[ad_1]

WALTHAM, Mass.–(BUSINESS WIRE)–Corindus
Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE
American: CVRS), a leading developer of precision vascular robotics,
will sponsor a breakfast symposium on May 21, 2019 titled, “Evolution of
Robotics: Automation, Remote Applications, and Beyond,” during the
Society for Cardiovascular Angiography and Interventions (SCAI) 2019
Scientific Sessions. The breakfast will be held in the Castellana
Ballroom 1 at the Cosmopolitan of Las Vegas in Las Vegas, NV from 6:45
a.m. to 7:45 a.m. PDT.

Chaired by Manish Parikh, M.D. of NewYork-Presbyterian Hospital/Columbia
University Medical Center, the symposium will feature esteemed faculty
Jon George, M.D. of Einstein Medical Center, William Lombardi, M.D. of
the University of Washington Medical Center, Ryan Madder, M.D. of
Spectrum Health, and Rajesh Swaminathan, M.D. of Duke University Medical
Center. Presentations will highlight advanced robotic capabilities,
including technIQ™ Smart Procedural Automation, milestones in remote
technology development, and clinical case reviews.

“With a number of crucial advancements in vascular robotics, we look
forward to sharing the latest milestones and developments with others in
the clinical community,” said Dr. Parikh. “Attendees can expect a
well-rounded assembly of presentations showcasing the many recent
improvements and capabilities in the robotic space, such as technIQ
automation, remote technology progress, and the role of robotics in
complex coronary and peripheral procedures.”

For SCAI attendees, space for the breakfast symposium is limited. For
more information and to register, please visit www.corindus.com/SCAI2019.
Attendees will also be able to schedule a hands-on demonstration of the
CorPath GRX System to be held in the exhibit hall at booth 407.
Reservations can be made at www.corindus.com/SCAI2019.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics is a global technology leader in
robotic-assisted vascular interventions. The Company’s CorPath® platform
is the first FDA-cleared medical device to bring robotic precision to
percutaneous coronary and vascular procedures. CorPath GRX is the second
generation robotic-assisted technology offering enhancements to the
platform by adding important key upgrades that increase precision,
improve workflow, and extend the capabilities and range of procedures
that can be performed robotically. We are focused on developing
innovative robotic solutions to revolutionize treatment of emergent
conditions by providing specialized and timely medical care to patients
around the world. For additional information, visit www.corindus.com,
and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or
current facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of Corindus to be materially different from historical results or from
any future results or projections expressed or implied by such
forward-looking statements. Accordingly, readers should not place undue
reliance on any forward-looking statements. In addition to statements
that explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as “believes,” “belief,” “expects,” “estimates,”
“intends,” “anticipates” or “plans” to be uncertain and forward-looking.
Forward-looking statements may include comments as to Corindus’ beliefs
and expectations as to future events and trends affecting its business
and are necessarily subject to uncertainties, many of which are outside
Corindus’ control.

Examples of such statements include statements regarding or such as:

  • That attendees can expect a well-rounded assembly of presentations
    showcasing the many recent improvements and capabilities in the
    robotic space.

Important factors that could cause actual results to differ materially
from those indicated by such forward-looking statements are described in
the sections titled “Risk Factors” in the Company’s filings with the
Securities and Exchange Commission, including its most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as
reports on Form 8-K, including, but not limited to the following: our
ability to expand our technology platform and achieve the advances
necessary for telestenting and remote procedures, including in humans;
our ability to expand our technology platform for use in other segments
of the vascular intervention market, including neurointerventional and
other more complex cardiac interventions; obtaining necessary regulatory
approvals for the use on humans and marketing of our products in the
United States and in other countries, including for stroke and other
neurovascular interventions; the rate of adoption of our CorPath System
and the rate of use of our cassettes; risks associated with market
acceptance, including pricing and reimbursement; our ability to enforce
our intellectual property rights; our need for additional funds to
support our operations; our ability to manage expenses and cash flow;
factors relating to engineering, regulatory, manufacturing, sales and
customer service challenges; potential safety and regulatory issues that
could slow or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More information
is available on Corindus’ website at http://www.corindus.com.

[ad_2]

Source link